Erratum: Acamprosate modulates experimental autoimmune encephalomyelitis, (Inflammopharmacol, 2012, 20, 1, 39-48, 10.1007/s10787-011-0097-1);Acamprosate modulates experimental autoimmune encephalomyelitis

Inflammopharmacology

Volumn 20, Issue 1, 2012, Pages 39-48

  Sternberg, Z ^a   Cesario, A ^a   Rittenhouse Olson, K ^b   Sobel, R A ^c   Pankewycz, O ^d   Zhu, B ^e   Whitcomb, T ^a   Sternberg, D S ^a   Munschauer, F E ^a  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acamprosate; Body weight; EAE; Multiple sclerosis; Taurine; Tumor necrosis factor

Indexed keywords

ACAMPROSATE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; DRUG DERIVATIVE; LIPOPOLYSACCHARIDE; TAURINE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DEMYELINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; EVENING DOSAGE; FEMALE; MORNING DOSAGE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; WEIGHT REDUCTION; ANIMAL; BLOOD BRAIN BARRIER; BODY WEIGHT; C57BL MOUSE; DEMYELINATING DISEASE; DRUG EFFECT; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; BODY WEIGHT; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; PILOT PROJECTS; TAURINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861310657     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-012-0120-1     Document Type: Erratum

References (45)

1. Barua M, Liu Y, Quinn MR (2001) Taurine chloramine inhibits inducible nitric oxide synthase and TNF-alpha gene expression in activated alveolar macrophages: decreased NF-kappaB activation and IkappaB kinase activity. J Immunol 167:2275-2281.
2. Bhat R, Axtell R, Mitra A, Miranda M, Lock C, Tsien RW, Steinman L (2010) Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci USA 107:2580-2585.
3. Bolton C, Paul C (1997) MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J Pharmacol Exp Ther 282:397-402.
4. Bowers MS, Chen BT, Chou JK, Osborne MP, Gass JT, See RE, Bonci A, Janak PH, Olive MF (2007) Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats. Psychopharmacology (Berl) 195:397-406.
5. Brasser SM, McCaul ME, Houtsmuller EJ (2004) Alcohol effects during acamprosate treatment: a dose-response study in humans. Alcohol Clin Exp Res 28:1074-1083.
6. Burattini C, McGeehan AJ, Griffin WC 3rd, Gass JT, Kinder JR, Janak PH, Olive MF (2008) A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration. Addict Biol 13:70-79.
7. Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, Musella A, D'Amelio M, Cavallucci V, Martorana A, Bergamaschi A, Cencioni MT, Diamantini A, Butti E, Comi G, Bernardi G, Cecconi F, Battistini L, Furlan R, Martino G (2009) Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 29:3442-3452.
8. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Martino G (2010) The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ 17:1083-1091.
9. Courtyn J, Cornelissen B, Oltenfreiter R, Vandecapelle M, Slegers G, Strijckmans K (2004) Synthesis and assessment of [11C]acetylhomotaurine as an imaging agent for the study of the pharmacodynamic properties of acamprosate by positron emission tomography. Nucl Med Biol 31:649-654.
10. Czachowski CL, Delory MJ (2009) Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats. Psychopharmacology (Berl) 204:335-348.
11. Dahchour A, De Witte P (2000) Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol 60:343-362.
12. De Witte P (2004) Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict Behav 29:1325-1339.
13. Engelhard K, Werner C, Lu H, Mollenberg O, Zieglgansberger W, Kochs E (2000) The neuroprotective effect of the glutamate antagonist acamprosate following experimental cerebral ischemia. A study with the lipid peroxidase inhibitor u-101033e. Anaesthesist 49:816-821.
14. Gupta RC, Win T, Bittner S (2005) Taurine analogues; a new class of therapeutics: retrospect and prospects. CurrMed Chem 12:2021-2039.
15. Kanayama A, Inoue J, Sugita-Konishi Y, Shimizu M, Miyamoto Y (2002) Oxidation of Ikappa Balpha at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-kappa B activation. J Biol Chem 277:24049-24056.
16. Kast RE, Altschuler EL (2007) Consideration of acamprosate for treatment of amyotrophic lateral sclerosis. Med Hypotheses 69:836-837.
17. Kiefer F, Jahn H, Otte C, Nakovics H, Wiedemann K (2006) Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference. Neurosci Lett 404:103-106.
18. Kril JJ, Halliday GM (1999) Brain shrinkage in alcoholics: a decade on and what have we learned? Prog Neurobiol 58:381-387.
19. Lenzi D, Conte A, Mainero C, Frasca V, Fubelli F, Totaro P, Caramia F, Inghilleri M, Pozzilli C, Pantano P (2007) Effect of corpus callosum damage on ipsilateral motor activation in patients with multiple sclerosis: a functional and anatomical study. Hum Brain Mapp 28:636-644.
20. Mann K, Lehert P, Morgan MY (2004) The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 28:51-63.
21. Manyam NV, Katz L, Hare TA, Gerber JC 3rd, Grossman MH (1980) Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders. Arch Neurol 37:352-355.
22. Mas-Serrano P, Granero L, Martin-Algarra RV, Guerri C, Polache A (2000) Kinetic study of acamprosate absorption in rat small intestine. Alcohol Alcohol 35:324-330.
23. McGeehan AJ, Olive MF (2003) The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but notmorphine. Br J Pharmacol 138:9-12.
24. Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK (2010) Animal models of multiple sclerosis-potentials and limitations. Prog Neurobiol 92:386-404.
25. Morgen K, Sammer G, Courtney SM, Wolters T, Melchior H, Blecker CR, Oschmann P, Kaps M, Vaitl D (2007) Distinct mechanisms of altered brain activation in patients with multiple sclerosis. Neuroimage 37:937-946.
26. Nalpas B, Dabadie H, Parot P, Paccalin J (1990) Acamprosate. From pharmacology to therapeutics. Encephale 16:175-179.
27. Newcombe J, Uddin A, Dove R, Patel B, Turski L, Nishizawa Y, Smith T (2008) Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 18:52-61.
28. Pierrefiche O, Daoust M, Naassila M (2004) Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology 47:35-45.
29. Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6:67-70.
30. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659-661.
31. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G (1998) Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 35:331-345.
32. Schaffer S, Azuma J, Takahashi K, Mozaffari M (2003) Why is taurine cytoprotective? Adv Exp Med Biol 526:307-321.
33. Simonini MV, Polak PE, Sharp A, McGuire S, Galea E, Feinstein DL (2010) Increasing CNS noradrenaline reduces EAE severity. J Neuroimmune Pharmacol 5:252-259.
34. Smith T, Groom A, Zhu B, Turski L (2000) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6:62-66.
35. Spanagel R, Zieglgansberger W (1997) Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 18:54-59.
36. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D (2005) Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128:1016-1025.
37. Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL (2004) Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J Immunol 173:5298-5304.
38. Wallstrom E, Diener P, Ljungdahl A, Khademi M, Nilsson CG, Olsson T (1996) Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 137:89-96.
39. Wang GH, Jiang ZL, Fan XJ, Zhang L, Li X, Ke KF (2007) Neuroprotective effect of taurine against focal cerebral ischemia in rats possibly mediated by activation of both GABAA and glycine receptors. Neuropharmacology 52:1199-1209.
40. Weiner HL (2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65:239-248.
41. Wu JY, Wu H, Jin Y, Wei J, Sha D, Prentice H, Lee HH, Lin CH, Lee YH, Yang LL (2009) Mechanism of neuroprotective function of taurine. Adv Exp Med Biol 643:169-179.
42. Zagon IS, Rahn KA, Turel AP, McLaughlin PJ (2009) Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp Biol Med (Maywood) 234:1383-1392.
43. Zalewska-Kaszubska J, Cwiek W, Dyr W, Czarnecka E (2005) Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference. Neurosci Lett 388:45-48.
44. Zeise ML, Kasparov S, Capogna M, Zieglgansberger W (1993) Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 231:47-52.
45. Zornoza T, Cano-Cebrian MJ, Hipolito L, Granero L, Polache A (2006) Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats. Biopharm Drug Dispos 27:305-311.